Anixa Biosciences (ANIX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 40.0% versus a loss of 41.1%. Over five years, ANIX leads with a -33.9% price change compared with -88.8% for PDSB. Anixa Biosciences is the larger company by market cap ($100.8 million vs $100.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | PDSB |
|---|---|---|
| Share price | $2.90 | $1.38 |
| Market cap | $100.82M | $100.01M |
| 1-day change | -0.34% | +35.29% |
| YTD return | -7.05% | +79.22% |
| 1-year return | -41.06% | +39.96% |
| 5-year return | -33.94% | -88.81% |
| EPS (TTM) | $-0.32 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $1.55 |
| 52-week low | $2.32 | $0.195 |
| Distance from 52-week high | -46.89% | -10.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +236.21% | +262.32% |
| Average volume | 304.71K | 23.24M |
| Shares outstanding | 34.76M | 72.47M |
| Employees | 4 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed ANIX by 81.0 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ANIX vs PDSB FAQ
Which is bigger, Anixa Biosciences or PDS Biotechnology?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $100.82M compared with $100.01M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, ANIX or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -41.06% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.